Amneal Pharmaceuticals, Inc. cash flow to debt ratio of 12.42% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Amneal Pharmaceuticals, Inc.'s free cash flow has increased 22.63% from $220.11M last year to $269.93M, signaling increasing performance

Amneal Pharmaceuticals, Inc.'s debt to equity ratio is 84.54, which means that the company's assets are unhealthy financed, signaling financial risk.

Amneal Pharmaceuticals, Inc.'s debt has increased relative to shareholder equity from -23.73 last year to 84.54 today, signaling weakened financials

Amneal Pharmaceuticals, Inc. has a net debt to EBITDA ratio of 4.02x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Amneal Pharmaceuticals, Inc.'s interest coverage ratio is 1.77, which means that the company struggles to meet interest obligations, signaling financial risk.

Amneal Pharmaceuticals, Inc.'s profit margin has increased (-220.66%) in the last year from -4.18% to 5.05%, signaling increasing performance

Amneal Pharmaceuticals, Inc.'s short-term assets of $1.91B exceed its short-term liabilities of $881.63M

Amneal Pharmaceuticals, Inc.'s return on assets of 4.17% is lower than the 5.00% threshold, indicating inefficient asset utilization

Amneal Pharmaceuticals, Inc.'s return on equity of -326.75%, is lower than 15.00%, indicating bad performance

Amneal Pharmaceuticals, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Amneal Pharmaceuticals, Inc. had positive net income in only 2 out of 5 years, indicating unstable earnings

Amneal Pharmaceuticals, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Amneal Pharmaceuticals, Inc. has a free cash flow yield of 4.73%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Amneal Pharmaceuticals, Inc.'s yearly earnings has increased -161.65% since last year from $-116.89M to $72.06M, signaling increasing performance

Amneal Pharmaceuticals, Inc.'s yearly revenue has increased 8.05% since last year from $2.79B to $3.02B, signaling increasing performance

ROIC 13.38% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Amneal Pharmaceuticals, Inc.'s 3-year revenue CAGR of 10.92% is positive, indicating growing revenue over the past 3 years

Amneal Pharmaceuticals, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Amneal Pharmaceuticals, Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Amneal Pharmaceuticals, Inc. is overvalued relative to its fair value price of 1.04 based on Discounted Cash Flow model

Amneal Pharmaceuticals, Inc. has an earnings yield of 2.76%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Amneal Pharmaceuticals, Inc. is overvalued relative to its fair value price of 5.65 based on EBITDA multiple model

Amneal Pharmaceuticals, Inc. has an EV/EBITDA ratio of 13.47x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Amneal Pharmaceuticals, Inc. is undervalued relative to its fair value price of 18.33 based on Earnings Fair Value model

Amneal Pharmaceuticals, Inc.'s earnings growth over the measurement period is negative; the PEG ratio is not meaningful and the check fails.

Amneal Pharmaceuticals, Inc. has a price-to-book ratio of 48.79x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Amneal Pharmaceuticals, Inc. has a price-to-sales ratio of 1.83x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue